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replication and genome stability. The very
exciting identification of KDM4A overex-
pression and its association with ovarian
cancer clearly has provided the field with
yet another chromatin-modifying enzyme
that can be used as a possible therapeutic
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ER-associated degradation clears the secretory pathway of misfolded proteins and mediates the
regulated degradation of some ER resident proteins. Only a minor increase in the interaction
between a protein and a ubiquitin ligase is sufficient to signal substrate degradation. Zhang et al.
have identified deubiquitination as a signal amplifier.The decision to destroy misfolded pro-
teins in the cell is not made lightly, as
there is always the hope that proteins
having transitional conformations may
simply be en route to their native struc-
tures. This is especially true in the secre-
tory pathway because soluble misfolded
substrates are recognized in the lumen
of the endoplasmic reticulum (ER) and
then must be exported into the cyto-
plasm, where they are destroyed via
the ubiquitin-proteasome pathway. This
process is known as ER-associated
degradation (ERAD). The ERAD of integral
membrane proteins presents a special
challenge, as membrane-spanning do-
mains must be liberated from the lipid
bilayer before the protein is threadedinto the 26S proteasome. Genetic and
in vitro analyses have delineated the
varied pathways taken during the degra-
dation of membrane proteins, with the
spotlight directed at E3 ligases that
append ubiquitin onto a proteasome-tar-
geted substrate. In this issue of Cell,
Hegde and colleagues redirect the spot-
light toward an opposing reaction, the
processive removal of the polyubiquitin
chain, which amplifies subtle differences
in E3-client interactions to generate a
polyubiquitin chain that is sufficient
for proteasome-mediated degradation
(Zhang et al., 2013).
Mammals encode > 600 E3s, so one
might envision that each E3 recognizes a
misfolded conformation adopted by asubset of the proteome (Varshavsky,
2012). In turn, each protein might be iden-
tified by a select group of E3s. Indeed,
functional redundancy among E3-client
interactions is frequently observed. How-
ever, due to complexities inherent in the
folding pathway, a protein displays a
range of misfolded conformations. More-
over, previous studies uncovered rela-
tively minor differences in the recognition
of an ERAD substrate versus its wild-
type counterpart by an E3 ubiquitin ligase
(Gardner et al., 2001; Ishikura et al., 2010;
Meacham et al., 2001). How are these
differences magnified to ensure that
folding-competent proteins do not fall
victim to the ubiquitin-proteasome sys-
tem or do so rarely?54, August 1, 2013 ª2013 Elsevier Inc. 479
Figure 1. Substrate Discrimination during the Vpu-Dependent ERAD of CD4
(A) After phosphorylation by casein kinase 2, Vpu recruits the SCFbetaTrCP ubiquitin ligase (‘‘E3’’), which
ubiquitinates CD4 on cytoplasm-resident Lys side chains. Based on the strong interaction between Vpu
and CD4 (denoted by the three lines within the membrane), repeated cycles of ubiquitin addition and
removal occur, and the polyubiquitin chain is maintained. Ultimately, CD4 is degraded by the proteasome.
(B) An 30% reduction in Vpu-CD4 interaction (denoted by two lines within the membrane and experi-
mentally determined using theCD4-M1mutant) also results in substrate ubiquitination, although the length
of the polyubiquitin chain is somewhat shorter. In this case, after cycles of ubiquitin addition and removal,
the chain may be depleted, which prevents proteasome-mediated degradation.To address this question, Zhang et al.
co-opted an HIV product, Vpu, which
when phosphorylated recruits an E3
ligase (SCFbetaTrCP) to catalyze CD4
degradation in the ER. CD4 is the receptor
that HIV uses to enter host cells, and its
destruction prevents superinfection and
facilitates maturation of a viral coat pro-
tein (Nomaguchi et al., 2008). The authors
showed first that the transmembrane
domain (TMD) and the cytosolic region
of CD4 and Vpu associate. When assess-
ing how mutations in the TMD affect
CD4’s fate in transfected cells, even a
modest (30%) reduction in interaction
efficiency resulted in substantial effects
on substrate ubiquitination and degrada-
tion, which is in accord with previous
studies (see above). To better understand
the nature of this phenomenon, a ‘‘mini-
CD4’’ containing only the TMD and a
defined cytosolic region was constructed.
The substrate was then reconstituted into
liposomes in the presence or absence of
Vpu. When essential purified compo-
nents (E1 ubiquitin-activating enzyme,
E2 ubiquitin-conjugating enzyme, the E3,
ubiquitin) and ATP were added, Vpu-480 Cell 154, August 1, 2013 ª2013 Elsevierand phosphorylation-dependent poly-
ubiquitination of mini-CD4 was evident.
Unexpectedly and in contrast to the
results obtained in cells, there was little
change in substrate ubiquitination when
the TMD was mutated to compromise
mini-CD4 association with Vpu. Thus,
the reconstituted system lacked a factor
that is vital for substrate discrimination.
The identity of the missing factor
became apparent when the polyubiquitin
chain in a microsome-based CD4 expres-
sion system was examined. Zhang et al.
discovered that the longest polyubiquiti-
nated chains were enriched in these
vesicles compared to the reconstituted
system, suggesting that the chains had
been processively trimmed. One class of
factors that copurify with microsomes
and are absent from the proteoliposomes
is deubiquitinating enzymes (DUBs); a few
DUBs are ER associated and/or have
been implicated in ERAD (see, for
example, Sanyal et al., 2012; Sowa
et al., 2009). When the catalytic domain
of a DUB was titrated into the reconsti-
tuted system that contained Vpu and
either wild-type or TMD-mutated mini-Inc.CD4, the magnitude of substrate discrim-
ination rose. Because DUB activity
decreases the dwell time of a polyubiqui-
tinated substrate on an E3 and assuming
that an E3 continues to display even a
slight preference for one substrate over
another, repeated cycles of ubiquitination
and ubiquitin chain trimming may be
needed to deliver ERAD substrates to
the proteasome yet spare a protein that
binds the E3s with somewhat lower affin-
ity (Figure 1). This hypothesis was sup-
ported when data from a mathematical
model were analyzed.
The model developed by Hegde and
colleagues will prompt a search for sub-
strate-specific, ERAD-requiring DUBs,
especially as a relatively small number of
these enzymes have been characterized.
It will also be critical in future efforts to
determine whether DUB activity is suffi-
cient for discrimination or whether the
myriad domains that reside in DUBs are
needed to augment ERAD substrate bind-
ing and discrimination (Reyes-Turcu et al.,
2009). DUB activity may even regulate
components of the ERAD machinery. In
addition, the authors have used a sub-
strate whose degradation is most likely
chaperone independent, but the discrimi-
nation of most ERAD substrates is aided
by molecular chaperones that deliver
unfolded proteins to E3s (Vembar and
Brodsky, 2008). Furthermore, a future
challenge will be to determine whether
the DUB-dependent discrimination model
holds for other substrates, such as the
largest class of ERAD substrates, i.e.,
those that are misfolded. Finally, the
retrotranslocation, ubiquitination, and
degradation of soluble substrates are
tightly coupled, so repeated cycles of
ubiquitin addition and removal may be
absent. Nevertheless, the reconstitution
of regulated CD4 ubiquitination pro-
vides an elegant system to examine the
interplay between E3s and DUBs, a
pursuit of great significance as many
E3s associate with DUBs. Together, the
DUBs are clearly important actors in
ERAD substrate discrimination, and their
time to share the spotlight with E3s has
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The selective breeding of rats as physiological, behavioral, and diseasemodels generated a wealth
of variation relevant to the genetics of complex traits. In this issue, Atanur and colleagues sequence
the genomes of 25 inbred rat strains to understand how artificial selection shaped their genomes.Humans and rats have shared habitats for
millennia, an intimacy that has seldom
engendered respect. We use rats as met-
aphors for human frailties and the most
unseemly aspects of our nature, including
disloyalty, opportunism, and unwhole-
some smell. Scientists, however, have
come to appreciate many more analogies
between rats and humans: some 1.5
million biomedical research papers—the
most for any model organism—testify to
the rat’s value as amodel for human phys-
iology and disease. In this issue, Atanur
et al. (2013) probe the genomic conse-
quences of humans’ selective breeding
of rats to model human diseases.
Rats’ strengths as a model for human
biology are compelling. Not only do rats
share much of our genomes, they also
share our dwellings and our food. Rats
have served as laboratory animals since
the early 1800s, when they were used to
study the effects of fasting and nutrition.
Large-scale selective breeding began in
1909, the same year as comparable ef-
forts for the mouse (Jacob, 1999). But
thenceforth, rats and mice took different
paths through the maze of human scienti-
fic aspiration.
The rat’s greater size and cognitive
capacity made it the preferred choice for
physiological experiments and studies oflearning andother behaviors: experimental
manipulations are easier in a larger animal,
and behavioral studies are richer in a
smarter one. The rat’s calm demeanor
and generous proportions are more for-
giving of human experimenters, facilitating
reproducibility. As laboratory animals, rats
contributed to most of the pharmaceuti-
cals of the 20th century—an extraordinary
contribution to human health.
Mice, by contrast, excelled as a genetic
model. Small and exuberantly reproduc-
tive, mice are suited to large, multigenera-
tional breeding experiments. Mice also
got a genetic head start from humans’
tendency to find mice cute. Early mouse
breeders enjoyed a lively market for
mice selected for unusual coat colors
and odd behaviors, such as ‘‘waltzing,’’
a neurological disorder in which mice
lurch in circles instead of walking in a
straight line. (One wonders whether the
same behavior in rats would have been
granted as charming a name.) Propaga-
tion by mouse ‘‘fanciers’’ produced
many strains and genetic markers (Wade
et al., 2002). Above all, though, the more
facile culturing of mouse embryonic
stem cells for knockout and transgenic
experiments would accelerate the scienti-
fic utilization of mice in the genome era
(Figure 1).The breeding of rats to scientific ends
was hardly neglected; scientists bred
more than 500 inbred strains of rat
(Aitman et al., 2008), including models
for hypertension, obesity, diabetes, multi-
ple sclerosis, and scores of other human
diseases. However, such breeding often
took a different form than in the mouse.
Laboratory rat strains were bred to
enhance specific phenotypes or traits
but only rarely backcrossed to deter-
mine whether the traits of interest were
mono- or polygenic. These practices
preserved complex patterns of genetic
causation, creating a valuable asset for
the study of polygenic phenotypes. The
rat was the first vertebrate (indeed, the
first non-plant) in which quantitative trait
locus (QTL) mapping was successfully
performed (James and Lindpaintner,
1997). Today, rats’ utility for mapping
complex traits is increasing with modern
genetic tools: the Rat Genome Database
reports 995 mapped QTLs, and a new
study maps another 355 QTLs for 122
phenotypes in the outbred descendants
of eight classic inbred rat strains (Baud
et al., 2013).
Many genetic insights are hidden in the
variation preserved in artificially selected
strains, but reaching these insights
requires this variation to be ascertained54, August 1, 2013 ª2013 Elsevier Inc. 481
